Hengrui Medicine: Approved for clinical trials of Irinotecan Hydrochloride

Hengrui Medicine announced that its subsidiary, Shanghai Hengrui Medicine Co., Ltd., has received the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration for Irinotecan Hydrochloride Liposome Injection (II), and clinical trials will be conducted soon.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin